Kingdon Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Kingdon Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-300,000	Closed	-$7.3M	–	128
2018 Q2	$7.3M	Buy	+300,000	New	+$6.12M	0.51%	72
2014 Q3	–	Sell	-300,000	Closed	-$15.7M	–	190
2014 Q2	$15.7M	Buy	+300,000	New	+$15.3M	0.6%	49

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Kingdon Capital Management's TEVA Position: Q2 2015 in Review

Kingdon Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 40,000 shares — an estimated $2.49M sold.

Kingdon Capital Management first reported a position in TEVA in Q2 2013 and held it in 3 quarters. The position peaked at $10.5M in Q2 2014. 819 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

Kingdon Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Kingdon Capital Management sold 40,000 Teva Pharmaceuticals shares in Q2 2015, an estimated $2.49M.
Kingdon Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 3 quarters.
Kingdon Capital Management's Teva Pharmaceuticals position peaked at $10.5M in Q2 2014.
819 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Kingdon Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.